Stock Update On Cbis And Nuec: Keep An Eye Out For Thursday - Pennytobuck.com

NuEarth Corporation (Pink Sheets:NUEC)

NuEarth Corporation (Pink Sheets:NUEC)

NUEC a manufacturer and marketer of "Clean & Green" products and technology, reported that NUEC's Laboratory and Research Division "TerraSolv SA" has renegotiated and finalized its Joint Venture Agreement with Laboratorio Internazionale Agricoltura, S/p/A ("LIA") of Italy.

The Finalizing of the Joint Venture Continuation Agreement brings 2 new laboratory projects to TerraSolv.

These projects are valued currently valued at more than $1.5 Million over the three-month work schedule starting in October 2010.

However, each contact has provisions that could triple the final contact value to more than $6 Million USD over their 12 month life cycle.

"We've seen incredible value from the lab, which has paid for itself several times over in its first year of operations. It represents a new, higher standard for doing business in IT throughout the environmental and agricultural industries. We're taking more risk out of the system, putting more structure into it, suffering less downtime and delivering higher-quality services," said Levi Modelevi - CEO of NUEC the parent of TerraSolv SA.

The TerraSolv SA Laboratory has generated more than $32 Million over its 3 year existence Mostly due to the Joint Venture with Laboratorio Internazionale Agricoltura, S/p/A.

NuEarth is a company dedicated to bringing to market "Clean Solutions to Complex Problems" by offering a wide range of biodegradable, environmentally friendly products and technologies that will substitute for many of the hazardous chemicals commonly used all over the world. For information about NuEarth and its product offerings visit us on the web at www.nuearthcorp.com

The agreement will continue to utilize the TerraSolv SA state-of-the-art development and testing lab currently being relocated to the United States of America. This data center, which collects data from clients around the world to run projects ranging from usability, capacity, spread and weather modeling and performance testing. The heart of the laboratory is a 225-gigabyte database of environmental and agricultural project records running on six HP servers and two Novell servers storing the data and running the software being tested.

TerraSolve/LIA is a state-of-the-art development and testing lab, which collects data from clients around the world to run projects simulations ranging from usability, capacity, spread and weather modeling testing. The heart of the laboratory is a 160-gigabyte database of environmental and agricultural project records running on six HP servers and two Novell servers storing the data and running the modeling software.

Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment.

In this multi-billion dollar market, this is very encouraging news for CBIS shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.

McGills study is the first double-blind, placebo-controlled trial conducted with outpatients who were allowed to smoke marijuana in their own homes. Participants were divided into four groups and randomly assigned marijuana containing four levels of tetrahydrocannabinol (THC), the active ingredient: at 9.4 per cent, 6.0 per cent, 2.5 per cent, and zero THC.

The study was led by anesthesiologist Mark Ware, director of clinical research at Montreals Alan Edwards Pain Management Unit at the McGill University Health Centre. It was published in the Canadian Medical Association Journal. Please see: http://www.cmaj.ca/cgi/rapidpdf/cmaj.091414v1?ijkey=44cf2a4e01bb03581946f0ab6b7217d7a6e78f0b

Richard Cowan, Cannabis Science CFO, added, This study demonstrates the importance of our licensing agreement with the RockBrook dispensary of Denver which we announced on August 18th, which gives us the immediate ability to test our formulations with humans to help determine exactly what doses and strains work best for patients as we prepare to enter clinical trials.?See?http://cannabisscience.com/news-a-media/press-releases/200-cbis-signs-first-licensing-agreement-with-rockbrook.html

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. CBIS works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received three thousand five hundred dollars from a third party (Paaga Media) for one (1) day of advertising for NuEarth Corp. (NUEC.PK).

by: Bill Pennyman

POST COMMENT

Stock Updates On Crwe, Orfg, Gmxr And Cyn From Pennytobuck.com Discover Details About A Settlement Funding Immune System - Some Theories And The Truth What Is Brainwave Entrainment And What's For The Dos And Donts Of Curing Hermit Crabs Mites How To Maintain Fascia And Soffit Boards? Latest Mobile Phones: The Multimedia Gadgets with Beneficial Deals Embroidered Stocking Caps Are Favorite By People Of Any Ages Iron Battery And Byd Polarity Between Academic And Public Views In Discourse On Anglicisms Trichotillomania - Prevalent and Treatable Things Keep Better and Better for Apple What Are Stocks And How Do They Work